| Serial Number | 97786656 |
| Word Mark | PELAMOFY |
| Filing Date | Wednesday, February 8, 2023 |
| Status | 731 - SECOND EXTENSION - GRANTED |
| Status Date | Friday, August 1, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 11, 2024 |
| Goods and Services | Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, February 17, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Constellation Pharmaceuticals, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Boston, MA 02210 |
| Party Name | Constellation Pharmaceuticals, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Boston, MA 02210 |
| Event Date | Event Description |
| Saturday, February 11, 2023 | NEW APPLICATION ENTERED |
| Friday, February 17, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, November 6, 2023 | ASSIGNED TO EXAMINER |
| Monday, November 6, 2023 | NON-FINAL ACTION WRITTEN |
| Monday, November 6, 2023 | NON-FINAL ACTION E-MAILED |
| Monday, November 6, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, January 31, 2024 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Wednesday, January 31, 2024 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Friday, April 5, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, April 5, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, May 8, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Friday, April 5, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, April 29, 2024 | FINAL REFUSAL WRITTEN |
| Monday, April 29, 2024 | FINAL REFUSAL E-MAILED |
| Monday, April 29, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Wednesday, May 8, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, May 8, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, May 8, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, May 8, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, May 22, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, June 11, 2024 | PUBLISHED FOR OPPOSITION |
| Monday, February 3, 2025 | SOU TEAS EXTENSION RECEIVED |
| Monday, February 3, 2025 | SOU EXTENSION 1 FILED |
| Tuesday, February 4, 2025 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, May 9, 2025 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, June 11, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, August 6, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, February 4, 2025 | SOU EXTENSION 1 GRANTED |
| Friday, May 9, 2025 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Friday, May 9, 2025 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Friday, May 9, 2025 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Friday, May 9, 2025 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Friday, August 1, 2025 | SOU TEAS EXTENSION RECEIVED |
| Friday, August 1, 2025 | SOU EXTENSION 2 FILED |
| Friday, August 1, 2025 | SOU EXTENSION 2 GRANTED |